Outset Medical (NASDAQ:OM) EVP Marc Nash Sells 5,375 Shares

by · The Markets Daily

Outset Medical, Inc. (NASDAQ:OM – Get Free Report) EVP Marc Nash sold 5,375 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $27,520.00. Following the sale, the executive vice president owned 42,785 shares of the company’s stock, valued at $219,059.20. This trade represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Marc Nash also recently made the following trade(s):

  • On Wednesday, January 21st, Marc Nash sold 980 shares of Outset Medical stock. The shares were sold at an average price of $4.98, for a total transaction of $4,880.40.
  • On Wednesday, January 7th, Marc Nash sold 108 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total value of $461.16.
  • On Monday, November 17th, Marc Nash sold 247 shares of Outset Medical stock. The shares were sold at an average price of $4.60, for a total value of $1,136.20.

Outset Medical Stock Up 3.0%

OM stock traded up $0.15 during trading on Wednesday, reaching $5.20. 256,678 shares of the company were exchanged, compared to its average volume of 1,737,004. Outset Medical, Inc. has a twelve month low of $3.10 and a twelve month high of $21.98. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The company has a 50-day moving average of $4.34 and a two-hundred day moving average of $11.07.

Institutional Investors Weigh In On Outset Medical

Hedge funds have recently made changes to their positions in the company. Alyeska Investment Group L.P. boosted its holdings in shares of Outset Medical by 10.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock valued at $22,798,000 after buying an additional 150,000 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Outset Medical by 34.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after purchasing an additional 131,381 shares during the last quarter. Pura Vida Investments LLC lifted its stake in Outset Medical by 8,482.4% during the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock valued at $8,243,000 after acquiring an additional 424,120 shares during the period. Millennium Management LLC grew its position in Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after purchasing an additional 262,874 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Outset Medical by 955.9% in the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after acquiring an additional 376,196 shares during the period.

Wall Street Analysts Forecast Growth

OM has been the topic of several analyst reports. BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of Outset Medical in a research report on Tuesday, December 16th. Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Finally, Stifel Nicolaus decreased their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

Check Out Our Latest Research Report on OM

About Outset Medical

(Get Free Report)

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.

Featured Stories